The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van der Vliet, H. J. J.
Right arrow Articles by Pinedo, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Vliet, H. J. J.
Right arrow Articles by Pinedo, H. M.
The Journal of Immunology, 2002, 168: 1490-1495.
Copyright © 2002 by The American Association of Immunologists

Selective Decrease in Circulating V{alpha}24+V{beta}11+ NKT Cells During HIV Type 1 Infection1

Hans J. J. van der Vliet*, B. Mary E. von Blomberg{dagger}, Mette D. Hazenberg§, Nobusuke Nishi*, Sigrid A. Otto§, Birgit H. van Benthem, Maria Prins, Frans A. Claessen{ddagger}, Alfons J. M. van den Eertwegh*, Giuseppe Giaccone*, Frank Miedema§, Rik J. Scheper2,*,{dagger} and Herbert M. Pinedo*

Departments of * Medical Oncology, {dagger} Pathology, and {ddagger} Internal Medicine, Free University Medical Center, Amsterdam, The Netherlands; § Department of Clinical Viro-Immunology, CLB, and the Laboratory for Experimental and Clinical Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; and Cluster of Infectious Diseases, Municipal Health Service, Amsterdam, The Netherlands


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
CD1d-restricted NKT cells express an invariant TCR and have been demonstrated to play an important regulatory role in a variety of immune responses. Invariant NKT cells down-regulate autoimmune responses by production of type 2 cytokines and can initiate antitumor and antimicrobial immune responses by production of type 1 cytokines. Although defects in the (invariant) V{alpha}24+V{beta}11+ NKT cell population have been observed in patients with cancer and autoimmune diseases, little is known regarding the protective role of V{alpha}24+V{beta}11+ NKT cells in human infectious disease. In a cross-sectional study in HIV-1-infected individuals, we found circulating numbers of V{alpha}24+V{beta}11+ NKT cells to be reduced, independent of CD4+ T cell counts, CD4:CD8 ratios, and viral load. Because a small minority of V{alpha}24+V{beta}11+ NKT cells of healthy donors expressed HIV-1 (co)receptors and the vast majority of V{alpha}24+V{beta}11+ NKT cells in HIV-1-infected individuals expressed the Fas receptor, the depletion was more likely due to Fas-mediated apoptosis than to preferential infection of V{alpha}24+V{beta}11+ NKT cells by HIV-1. A longitudinal cohort study, in which patients were analyzed before seroconversion and 1 and 5 years after seroconversion, demonstrated that a large proportion of the depletion occurred within the first year postseroconversion. In this longitudinal study no evidence was found to support an important role of V{alpha}24+V{beta}11+ NKT cells in determining the rate of progression during HIV-1 infection.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Natural killer T cells constitute a lymphocyte lineage sharing characteristics of both T cells and NK cells. NKT cells display an extremely restricted TCR repertoire, in humans consisting of a V{alpha}24 chain preferentially paired with a V{beta}11 chain, and recognize Ag in the context of the monomorphic CD1d Ag-presenting molecule (1, 2, 3). Although natural ligands are not known, NKT cells have been shown to recognize the {alpha}-anomeric glycolipid {alpha}-galactosylceramide ({alpha}-GalCer)3 when presented by CD1d (4, 5, 6). A potential role of NKT cells in the regulation of immune responses has been hypothesized because of their capacity to rapidly release large amounts of IL-4 and IFN-{gamma} upon activation (3, 7). Indeed, NKT cells have now been shown to play crucial roles in various immune responses, including antitumor, autoimmune, and antimicrobial immune responses (summarized in Ref. 8). Their regulatory role in immune responses that require opposite regulatory pathways has been attributed to an apparent flexibility of NKT cells with regard to their predominant cytokine profile. NKT cell-derived Th1 cytokines (e.g., IFN-{gamma}) are important in the initiation of antitumor immune responses while NKT cell-derived Th2 cytokines (e.g., IL-4 and IL-10) are involved in down-regulation of autoimmune responses (9, 10).

Murine NKT cells participate in immune responses to a range of different infectious agents, including Listeria, Toxoplasma, Mycobacteria, Salmonella, Plasmodium, and hepatitis (8, 11). The granulomatous reaction to Mycobacterium tuberculosis is dependent on NKT cells, and mycobacterial infection stimulates IFN-{gamma} production by NKT cells (12, 13). In MHC class II-deficient mice, NKT cells mediate the development of cell-mediated immunity to Toxoplasma gondii infection (14), and during infection with Plasmodium yoelii there was an increase in liver NKT cells, which directly inhibited growth of pathogen in hepatocytes in vitro via an IFN-{gamma}-dependent mechanism (15). Interestingly, {alpha}-GalCer-mediated activation of NKT cells was recently shown to mediate protection against both murine malaria and hepatitis B. IFN-{gamma} was essential for the anti-malaria effect of {alpha}-GalCer, while its antiviral effects were mediated by both IFN-{gamma} and IFN-{alpha}{beta} (11, 16).

At present, little is known about the potential role of NKT cells in human infectious diseases. Although NKT cells bridge innate and adaptive immune responses, both of which are important in controlling HIV infection (17, 18), and have been reported to exert antiviral effects via IFNs that are also capable of inhibiting HIV replication (19), no data are available on the role of NKT cells in HIV infection. In this work, we studied the size of the circulating V{alpha}24+V{beta}11+ NKT cell population during HIV-1 infection and evaluated whether differences in the size of the V{alpha}24+V{beta}11+ NKT cell population would affect HIV-1 disease progression.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Study population

Cross-sectional analyses were performed on a group of 46 healthy adult volunteers (mean age, 42 years; range, 21–83 years; 19 males and 27 females) and a group of 50 patients (mean age, 41 years; range, 19–59 years; 42 males and 8 females) with known HIV-1-positive status attending the outpatient clinic of the Department of Internal Medicine of the Free University Medical Center (Amsterdam, The Netherlands). Of the 50 HIV-1-infected patients, 37 received highly active antiretroviral therapy (HAART). Mean CD4+ T cell count was 362 cells/µl (range, 10–1180); mean CD4:CD8 ratio was 0.2 (range, <0.1–1); and mean viral load was 53194 copies/ml, viral load being undetectable in 30 patients. The longitudinal cohort study was performed using cryopreserved PBMC of 87 participants of the Amsterdam cohort studies on AIDS and HIV-1 infection in homosexual men (this study, which is ongoing, was initiated in 1984 in a collaboration between the Amsterdam Municipal Health Service, the Academic Medical Center at the University of Amsterdam, and the Central Laboratory of The Netherlands Red Cross Blood Transfusion Service). For cryopreservation, a computerized freezing device was used that resulted in optimal quality of viably frozen cells for functional studies (20), and frozen blood samples were stored in liquid nitrogen.

Flow cytometric analysis

In the cross-sectional study, leukocytes were prepared from heparinized peripheral blood using the ImmunoPrep Reagent System (Coulter, Miami, FL) and lymphocyte numbers were calculated using Simultest LeucoGATE reagent in combination with SimulSET software (BD Biosciences, San Jose, CA). Analysis of V{alpha}24+V{beta}11+ NKT cells in patients from the cohort study was performed on cryopreserved peripheral blood samples. Typically, 1–5 x 105 viable lymphocytes were evaluated for calculation of the frequency of V{alpha}24+V{beta}11+ NKT cells. The following Abs were used: FITC-labeled anti-human V{alpha}24 mAb, PE- and biotin-labeled anti-human V{beta}11 mAb (Immunotech, Marseille, France), R-PE-Cy5-labeled CD3 and CD4 mAb, R-PE-Cy5-labeled streptavidin (DAKO, Glostrup, Denmark), PE-labeled CD95 mAb (BD Biosciences), and PE-labeled CCR5 mAb (BD PharMingen, San Diego, CA). CD4/CD8 SimulSET was purchased from BD Biosciences. Flow cytometric analysis was performed on a FACStarPlus equipped with an argon ion laser (BD Biosciences).

Plasma HIV-1 RNA detection

Plasma HIV-1 RNA load was assessed using the ultrasensitive AMPLICOR HIV-1 MONITOR test version 1.5 (Roche Diagnostics, Indianapolis, IN).

Cell cultures

PBMC from healthy volunteers were allowed to adhere to culture flasks for 2 h at 37°C. Immature monocyte-derived dendritic cells (moDC) were then prepared from the adherent cells during a 7-day culture in the presence of recombinant human (rh)IL-4 (1000 U/ml; Central Laboratory of The Netherlands Red Cross Blood Transfusion Service Sanquin Blood Supply Foundation, Amsterdam, The Netherlands) and rhGM-CSF (100 ng/ml; Kirin Brewery, Gunma, Japan) in IMDM (BioWhittaker, Verviers, Belgium) supplemented with 10% FCS, 0.01 mM 2-ME, and 50 U/ml penicillin-streptomycin. Immature moDC were then matured for 3 days with rhTNF-{alpha} (50 ng/ml; Cetus, Amsterdam, The Netherlands) in the presence of 100 ng/ml {alpha}-GalCer (KRN7000). Mature {alpha}-GalCer-loaded moDC were washed and cocultured for 7 days with autologous nonadherent PBMC.

{alpha}-GalCer

{alpha}-GalCer ((2S,3S,4R)-1-O-({alpha}-D-galactopyranosyl)-2-(N-hexacosanoylamino)- 1,3,4-octadecanetriol) was synthesized by the Pharmaceutical Research Laboratory of the Kirin Brewery and dissolved in 100% DMSO. Final concentration of DMSO in cultures was 0.1%.

Statistical analysis

Statistical analyses were performed using the Mann-Whitney U test, Wilcoxon matched pairs test, Student t test, and rank correlation test. Cox proportional hazards analysis was used to evaluate the prognostic value of V{alpha}24+V{beta}11+ NKT cells for HIV-1 disease progression. A value of p < 0.05 was considered significant.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Circulating V{alpha}24+V{beta}11+ NKT cell numbers are decreased during HIV-1 infection

Cross-sectional analysis of a group of 50 HIV-1-infected and 46 healthy individuals revealed that circulating numbers of V{alpha}24+V{beta}11+ NKT cells (i.e., T cells expressing both the TCR V{alpha}24 and V{beta}11 chains) were significantly lower in HIV-1-infected individuals (HIV-1 group: median, 71.5; interquartile range (IQR), 25–257; and control group: median, 586.5; IQR, 308-1249; p < 0.0001; Mann-Whitney U test, Fig. 1Go, left panel). Cell numbers were calculated per 1 x 106 lymphocytes to correct for lymphopenia and lymphocytosis. Although the V{alpha}24 and V{beta}11 mAb used in our analyses do not molecularly identify the invariant TCR rearrangement of NKT cells, their combined use was shown to be highly specific for invariant NKT cells and allows calculation of circulating cell numbers (8, 21). Circulating numbers of V{alpha}24+V{beta}11- T cells were also reduced (HIV-1 group: median, 1336; IQR, 817-2136; and control group: median, 1512; IQR, 1194–2682; p = 0.03, Fig. 1Go, middle panel), but circulating numbers of T cells expressing only the V{beta}11 chain were comparable in HIV-1-infected individuals and in controls (HIV-1 group: median, 3750; IQR, 2886–5092; and control group: median, 4534; IQR, 3741–5163; p = 0.11, Fig. 1Go, right panel). Patients receiving and not receiving HAART had comparable circulating V{alpha}24+V{beta}11+ NKT cell numbers (Fig. 1Go, left panel; p = 0.31). Further evaluation revealed that there was no significant correlation between circulating V{alpha}24+V{beta}11+ NKT cell numbers and CD4:CD8 ratio (Fig. 2Go; correlation coefficient (r) = 0.12, p = 0.42, Spearman rank correlation test), CD4+ T cell counts (Fig. 2Go; r = -0.06, p = 0.67), or HIV-1 RNA viral load (Fig. 2Go; r = 0.18, p = 0.21). Similarly, there was no significant correlation between circulating V{alpha}24+V{beta}11+ NKT cell numbers and HIV-1 RNA viral load (r = 0.15, p = 0.66) or CD4+ T cell counts (r = 0.14, p = 0.69) when analysis was performed on patients not receiving HAART.



View larger version (12K):
[in this window]
[in a new window]
 
FIGURE 1. Decrease in circulating V{alpha}24+V{beta}11+ NKT cells during HIV-1 infection. Shown is a significant decrease in V{alpha}24+V{beta}11+ NKT cells (p < 0.0001, Mann-Whitney U test) and in V{alpha}24+V{beta}11- T cells (p = 0.03), but not in V{alpha}24-V{beta}11+ T cells (p = 0.11). Horizontal lines indicate the median. {blacktriangleup}, Patients receiving HAART; {triangleup}, patients not receiving HAART. Data represent a cross-sectional analysis of 50 HIV-1-positive patients and 46 healthy adult volunteers.

 


View larger version (12K):
[in this window]
[in a new window]
 
FIGURE 2. Correlation among circulating V{alpha}24+V{beta}11+ NKT cell numbers, CD4:CD8 ratio, CD4+ T cell counts, and viral load. No significant correlation was found between circulating V{alpha}24+V{beta}11+ NKT cells and CD4:CD8 ratio (r = 0.12, p = 0.42, Spearman rank correlation test), CD4+ T cell counts (r = -0.06, p = 0.67), or HIV-1 RNA viral load (r = 0.18, p = 0.21). Data represent cross-sectional analyses of 50 HIV-1-positive patients.

 
Kinetics of V{alpha}24+V{beta}11+ NKT cell depletion during HIV-1 infection

Because the exact duration of HIV-1 infection had not been recorded in the cross-sectional analysis, we set out to confirm and extend our findings by analyzing the frequency of V{alpha}24+V{beta}11+ NKT cells in cryopreserved PBMC of the Amsterdam cohort on HIV-1 infection in homosexual men. V{alpha}24+V{beta}11+ NKT cell frequencies were determined at three time points: before seroconversion, 1 year postseroconversion, and 5 years postseroconversion. Fig. 3GoA shows that the frequency of V{alpha}24+V{beta}11+ NKT cells (expressed as a percentage of T cells) significantly decreased during HIV-1 infection. The preseroconversion V{alpha}24+V{beta}11+ NKT cell frequency (median, 0.03; IQR, 0.01–0.08; n = 48) was significantly lower than in our control group (median, 0.08; IQR, 0.04–0.17; p = 0.02, Mann-Whitney U test). This frequency decreased to 0.02 (IQR, 0.01–0.04; n = 82) and 0.01 (IQR, 0–0.02; n = 50) at 1 and 5 years postseroconversion, respectively (preseroconversion vs 1 year postseroconversion, p < 0.0001 (Wilcoxon matched pairs test); preseroconversion vs 5 years postseroconversion, p < 0.0001; 1 vs 5 years postseroconversion, p = 0.0002). In contrast, the frequency of single V{beta}11+ T cells (expressed as a percentage of T cells) did not significantly change in the course of HIV-1 infection (preseroconversion vs 5 years postseroconversion, p = 0.054). Data are expressed as a percentage of T cells to correct for differences in total T cell numbers over time. Fig. 3GoB shows representative flow cytometric dot plots from one individual.



View larger version (25K):
[in this window]
[in a new window]
 
FIGURE 3. Selective depletion of V{alpha}24+V{beta}11+ NKT cells during HIV-1 infection. Cryopreserved PBMC samples of participants from the Amsterdam cohort studies on AIDS and HIV-1 infection in homosexual men were analyzed preseroconversion and at 1 and 5 years postseroconversion. A, A decrease in V{alpha}24+V{beta}11+ NKT cells (preseroconversion vs 5 years postseroconversion, p < 0.0001; Wilcoxon matched pairs test) but not in V{alpha}24-V{beta}11+ T cells (preseroconversion vs 5 years postseroconversion, p = 0.054). Data are expressed as a percentage of T cells; median, IQR, minimum, and maximum are shown. B, Sequential dot plots of CD3+ cells from one individual.

 
Expression of CD4, CCR5, and CD95 on V{alpha}24+V{beta}11+ NKT cells

One of the potential causes of the selective decrease in the size of the circulating V{alpha}24+V{beta}11+ NKT cell population could be their preferential infection by HIV-1. The HIV-1 virion enters its target cell through a sequence of conformational shifts initiated by binding to CD4. Primary HIV-1 infection is established with non-syncytium-inducing CCR5 coreceptor using HIV-1 variants (22, 23, 24, 25). First, we studied CD4 expression on V{alpha}24+V{beta}11+ NKT cells of healthy volunteers both before and after activation. CD4 expression was observed on 25 ± 8% (n = 5; data not shown) of circulating V{alpha}24+V{beta}11+ NKT cells. Although ligand-specific activation of V{alpha}24+V{beta}11+ NKT cells using {alpha}-GalCer-loaded moDC uniformly resulted in the expression of high levels of the activation marker CD25 (data not shown), it did not result in a significant up-regulation of CD4 expression on V{alpha}24+V{beta}11+ NKT cells (40 ± 21%, n = 5, p = 0.21, paired Student’s t test). Furthermore, because only 1.6 ± 1.9% (n = 4) of V{alpha}24+V{beta}11+ NKT cells was found to express both CD4 and CCR5, we think that it is unlikely that direct infection accounts for the depletion of the V{alpha}24+V{beta}11+ NKT cell population (Fig. 4GoA).



View larger version (19K):
[in this window]
[in a new window]
 
FIGURE 4. Expression of CD4, CCR5, and Fas on V{alpha}24+V{beta}11+ NKT cells. Shown are representative flow cytometric dot plots of expression of CD4 and CCR5 on V{alpha}24+V{beta}11+ NKT cells of a healthy donor (A) and of Fas expression on V{beta}11+ T cells of an HIV-1-infected patient (B).

 
Fas/Fas ligand (FasL) interactions represent an important apoptosis-enhancing pathway involved in T cell depletion during HIV infection (26). Therefore, we compared Fas (CD95) expression on V{alpha}24+V{beta}11+ NKT cells and single V{beta}11+ T cells in HIV-1-infected individuals and found that a significantly higher proportion of residual V{alpha}24+V{beta}11+ NKT cells expressed CD95 (93.4 ± 7.4% (mean ± SD) vs 63.4 ± 20.4%, n = 7, p = 0.005, paired Student’s t test). Fig. 4GoB shows a representative flow cytometric dot plot from one individual.

Prognostic relevance of the size of the V{alpha}24+V{beta}11+ NKT cell pool on HIV-1 progression

Because the circulating V{alpha}24+V{beta}11+ NKT cell frequency showed strong interindividual variability, we evaluated whether the size of the circulating V{alpha}24+V{beta}11+ NKT cell pool could predict disease progression during HIV-1 infection. Participants of the Amsterdam cohort on HIV-1 infection in homosexual men were split into two groups based on whether they had a circulating V{alpha}24+V{beta}11+ NKT cell frequency above or below the group median. The relative hazard (RH) of the group of participants with above-median circulating V{alpha}24+V{beta}11+ NKT cell frequencies was then compared with the group of participants with below-median circulating V{alpha}24+V{beta}11+ NKT cell frequencies with respect to the following AIDS-related endpoints: progression to AIDS (27), death from an AIDS-related cause, CD4+ T cell counts < 200/ml, and conversion to a syncytium-inducing viral variant (SI conversion). Analyses performed preseroconversion, 1 year postseroconversion, and 5 years postseroconversion clearly showed that relatively higher V{alpha}24+V{beta}11+ NKT cell frequencies were not predictive of a better outcome in HIV-1-infected patients (Table IGo). Similar results were obtained in multivariate analyses where results were corrected for viral HIV-1 RNA load and CD4+ T cell counts (data not shown).


View this table:
[in this window]
[in a new window]
 
Table I. Effect of the size of the V{alpha}24+V{beta}11+ NKT cell pool on HIV-1 progressiona

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Cross-sectional analysis of HIV-1-infected individuals and healthy controls demonstrated a decrease of circulating V{alpha}24+V{beta}11+ NKT cell numbers during HIV-1 infection. This decrease in circulating V{alpha}24+V{beta}11+ NKT cell numbers, which was not associated with either CD4+ T cell counts, CD4:CD8 ratios, or viral load, was confirmed in our longitudinal study. The latter analysis also demonstrated the time course of V{alpha}24+V{beta}11+ NKT cell depletion and indicated that a major proportion of the decrease in circulating V{alpha}24+V{beta}11+ NKT cells occurred within the first year postseroconversion.

The disappearance of V{alpha}24+V{beta}11+ NKT cells during HIV-1 infection is not likely to be the result of viral infection per se, because circulating V{alpha}24+V{beta}11+ NKT cell frequencies were recently reported to be normal during hepatitis C viral infection (21). Several factors could contribute to the depletion of the circulating V{alpha}24+V{beta}11+ NKT cell population, including sequestration, preferential infection, and activation-induced cell death. First, the rise in CD4+ and CD8+ T cell numbers during the first 4 wk of HAART is generally believed to be due to redistribution of previously sequestered memory lymphocytes from lymphoid tissues to the circulation (28). No relation between viral load and circulating V{alpha}24+V{beta}11+ NKT cell numbers could be found, and in several patients who showed CD4+ T cell responses upon institution of HAART circulating V{alpha}24+V{beta}11+ NKT cell numbers remained low (data not shown). However, to formally exclude the possibility that the depletion of the V{alpha}24+V{beta}11+ NKT cell population is the result of sequestration in the periphery, we are now systematically evaluating the effects of HAART on circulating V{alpha}24+V{beta}11+ NKT cell numbers. Second, it has been reported that the HIV-1 virion enters a target cell through a sequence of conformational shifts initiated by the binding of CD4 (25). Previously, we and others have reported that CD4 expression could be observed on a minority of circulating V{alpha}24+V{beta}11+ NKT cells (29, 30). Although CD8+ T cells can express CD4 upon activation, allowing HIV entry (31, 32), we found no evidence for a similar activation-induced up-regulation of CD4 expression on V{alpha}24+V{beta}11+ NKT cells. Because only 1.6 ± 1.9% of V{alpha}24+V{beta}11+ NKT cells expressed both CD4 and the coreceptor CCR5, we believe that it is unlikely that physical infection of V{alpha}24+V{beta}11+ NKT cells is responsible for the population depletion. Third, several reports indicate that ligation of the Fas receptor by FasL is an important factor involved in HIV-associated lymphocyte depletion. T cells from HIV-infected patients have been reported to exhibit both increased Fas receptor expression and enhanced susceptibility to Fas-mediated death (33, 34). Of note, both FasL expression on PBMC and plasma levels of soluble FasL are increased in HIV-positive patients (35, 36, 37). We found the Fas receptor to be expressed by the vast majority of residual circulating V{alpha}24+V{beta}11+ NKT cells. Because the proportion of V{alpha}24+V{beta}11+ NKT cells expressing the Fas receptor was significantly higher than that of single V{beta}11+ T cells, Fas-induced apoptosis might contribute to the observed selective depletion of the V{alpha}24+V{beta}11+ NKT cell population. HIV-1 infection has been demonstrated to increase cell division and death rates mainly by causing persistent immune activation (38). Therefore, one could hypothesize that the observed depletion of the V{alpha}24+V{beta}11+ NKT cell population is the result of a continuous process of activation-induced cell death. Because renewal of invariant NKT cells was demonstrated to be slow in both mouse and human (39).4 this could further contribute to the decrease in the size of the V{alpha}24+V{beta}11+ NKT cell population.

Infection with HIV-1 has been associated with various autoimmune syndromes and malignancies (40, 41, 42). Because defects in the invariant NKT cell population were reported in both animals and patients suffering from autoimmune disease or malignancy (8, 43, 44, 45, 46), it is tempting to speculate that the increased frequency of autoimmune phenomena and malignancies during HIV-1 infection is related to a decrease in the size of the V{alpha}24+V{beta}11+ NKT cell population. Because activated NKT cells could down-regulate hepatitis B viral replication in mice through production of IFN-{alpha}{beta} and IFN-{gamma} (11), cytokines previously reported to inhibit HIV replication (19), we hypothesized that V{alpha}24+V{beta}11+ NKT cells could slow down progression during HIV-1 infection. However, our data could not demonstrate a statistically significant relation between the circulating V{alpha}24+V{beta}11+ NKT cell frequency and several AIDS-related disease endpoints. In contrast to what we expected, individuals with higher preseroconversion or 1 year postseroconversion V{alpha}24+V{beta}11+ NKT cell frequencies tended to have even higher RHs, suggesting a potential immunosuppressive effect of V{alpha}24+V{beta}11+ NKT cells. Recent evidence indeed suggests that the natural role of NKT cells could be immunosuppressive in nature by predominant production of Th2 cytokines (47). Of interest, synthetic glycolipid analogs of {alpha}-GalCer were shown to differentially affect the cytokine profile of NKT cells (48). Therefore, because high-affinity TCR ligands preferentially induce Th1-type responses in T cells (49), stimulation of NKT cells by ligands that result in high-affinity interactions could shift NKT cell cytokine production toward a Th1 profile, thereby enhancing the establishment of a proinflammatory immune response (50). This would favor both antivirus and antitumor immune reactivity but could also increase the frequency of autoimmune phenomena during HIV infection. Therefore, although we report in this work that the size of the circulating V{alpha}24+V{beta}11+ NKT cell population does not affect the progression rate to several clinical and immunological endpoints, further studies are needed to examine the relationship between the cytokine profile of V{alpha}24+V{beta}11+ NKT cells and HIV-1 disease progression.

In conclusion, in this study we demonstrate for the first time the preferential depletion of the immunoregulatory V{alpha}24+V{beta}11+ NKT cell population during HIV-1 infection. Although this depletion is likely to contribute to the development of immunodeficiency, our data do not provide evidence to support an important role of V{alpha}24+V{beta}11+ NKT cells in determining the rate of progression during HIV-1 infection.


    Footnotes
 
1 This work was supported by a Spinoza grant and Grant NR 920-03-142 from The Netherlands Organization for Scientific Research. Back

2 Address correspondence and reprint requests to Dr. Rik J. Scheper, Department of Pathology, Free University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. E-mail address: rj.scheper{at}vumc.nl Back

3 Abbreviations used in this paper: {alpha}-GalCer, {alpha}-galactosylceramide; HAART, highly active antiretroviral therapy; rh, recombinant human; RH, relative hazard; moDC, monocyte-derived dendritic cell; IQR, interquartile range; FasL, Fas ligand. Back

4 G. Giaccone, C. Punt, Y. Ando, R. Ruÿter, N. Nishi, M. Peters, B. von Blomberg, R. Scheper, H. van der Vliet, A. van den Eertwegh, et al. A phase I study on the NKT cell ligand {alpha}-galactosylceramide (KRN7000) in patients with solid tumors. Submitted for publication. Back

Received for publication September 20, 2001. Accepted for publication December 3, 2001.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Porcelli, S., C. E. Yockey, M. B. Brenner, S. P. Balk. 1993. Analysis of T cell receptor (TCR) expression by human peripheral blood CD4-CD8- {alpha}{beta} T cells demonstrates preferential use of several V{beta} genes and an invariant {alpha} chain. J. Exp. Med. 178:1.[Abstract/Free Full Text]
  2. Bendelac, A., M. N. Rivera, S. H. Park, J. H. Roark. 1997. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 15:535.[Medline]
  3. Exley, M., J. Garcia, S. P. Balk, S. Porcelli. 1997. Requirements for CD1d recognition by human invariant V{alpha}24+CD4-CD8- T cells. J. Exp. Med. 186:109.[Abstract/Free Full Text]
  4. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al 1997. CD1d-restricted and TCR-mediated activation of V{alpha}14 NKT cells by glycosylceramides. Science 278:1626.[Abstract/Free Full Text]
  5. Brossay, L., M. Chioda, N. Burdin, Y. Koezuka, G. Casorati, P. Dellabona, M. Kronenberg. 1998. CD1d-mediated recognition of an {alpha}-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188:1521.[Abstract/Free Full Text]
  6. Spada, F. M., Y. Koezuka, S. A. Porcelli. 1998. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J. Exp. Med. 188:1529.[Abstract/Free Full Text]
  7. Chen, H., W. E. Paul. 1997. Cultured NK1.1+CD4+ T cells produce large amounts of IL-4 and IFN-{gamma} upon activation by anti-CD3 or CD1. J. Immunol. 159:2240.[Abstract/Free Full Text]
  8. Godfrey, D. I., K. J. L. Hammond, L. D. Poulton, M. J. Smyth, A. G. Baxter. 2000. NKT cells: facts, functions and fallacies. Immunol. Today 21:573.[Medline]
  9. Hammond, K. J. L., L. D. Poulton, L. J. Palmisano, P. A. Silveira, D. I. Godfrey, A. G. Baxter. 1998. {alpha}/{beta}-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187:1047.[Abstract/Free Full Text]
  10. Hayakawa, Y., K. Takeda, H. Yagita, S. Kakuta, Y. Iwakura, L. van Kaer, I. Saiki, K. Okumura. 2001. Critical contribution of IFN-{gamma} and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of {alpha}-galactosylceramide. Eur. J. Immunol. 31:1720.[Medline]
  11. Kakimi, K., L. G. Guidotti, Y. Koezuka, F. V. Chisari. 2000. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 192:921.[Abstract/Free Full Text]
  12. Apostolou, I., Y. Takahama, C. Belmant, T. Kawano, M. Huerre, G. Marchal, J. Cui, M. Taniguchi, H. Nakauchi, J. J. Fournie, et al 1999. Murine natural killer T (NKT) cells contribute to the granulomatous reaction caused by mycobacterial cell walls. Proc. Natl. Acad. Sci. USA 96:5141.[Abstract/Free Full Text]
  13. Emoto, M., Y. Emoto, I. B. Buchwalow, S. H. Kaufmann. 1999. Induction of IFN-{gamma}-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette-Guerin. Eur. J. Immunol. 29:650.[Medline]
  14. Denkers, E. Y., T. Scharton-Kersten, S. Barbieri, P. Caspar, A. Sher. 1996. A role for CD4+NK1.1+ T lymphocytes as major histocompatibility complex class II independent helper cells in the generation of CD8+ effector function against intracellular infection. J. Exp. Med. 184:131.[Abstract/Free Full Text]
  15. Pied, S., J. Roland, A. Louise, D. Voegtle, V. Soulard, D. Mazier, P. A. Cazenave. 2000. Liver CD4-CD8-NK1.1+ TCR {alpha}{beta} intermediate cells increase during experimental malaria infection and are able to exhibit inhibitory activity against the parasite liver stage in vitro. J. Immunol. 164:1463.[Abstract/Free Full Text]
  16. Gonzalez-Aseguinolaza, G., C. de Oliveira, M. Tomaska, S. Hong, O. Bruna-Romero, T. Nakayama, M. Taniguchi, A. Bendelac, L. van Kaer, Y. Koezuka, M. Tsuji. 2000. {alpha}-Galactosylceramide-activated V{alpha}14 natural killer T cells mediate protection against murine malaria. Proc. Natl. Acad. Sci. USA 97:8461.[Abstract/Free Full Text]
  17. Levy, J. A.. 2001. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol. 22:312.[Medline]
  18. McMichael, A. J., S. L. Rowland-Jones. 2001. Cellular immune responses to HIV. Nature 410:980.[Medline]
  19. Meylan, P. R., J. C. Guatelli, J. R. Munis, D. D. Richman, R. S. Kornbluth. 1993. Mechanisms for the inhibition of HIV replication by interferons-{alpha}, -{beta}, and -{gamma} in primary human macrophages. Virology 193:138.[Medline]
  20. Bom-van Noorloos, A. A., A. A. van Beek, C. J. Melief. 1980. Cryopreservation of cells for immunological typing of non-Hodgkin’s lymphomas. Cancer Res. 40:2890.[Abstract/Free Full Text]
  21. Karadimitris, A., S. Gadola, M. Altamirano, D. Brown, A. Woolfson, P. Klenerman, J. L. Chen, Y. Koezuka, I. A. Roberts, D. A. Price, et al 2001. Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc. Natl. Acad. Sci. USA 98:3294.[Abstract/Free Full Text]
  22. Doranz, B. J., J. Rucker, Y. Yi, R. J. Smyth, M. Samson, S. C. Peiper, M. Parmentier, R. G. Collman, R. W. Doms. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 28:1149.
  23. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, et al 1996. The {beta}-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 28:1135.
  24. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, et al 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661.[Medline]
  25. Doms, R. W.. 2000. Beyond receptor expression: the influence of receptor conformation, density and affinity in HIV-1 infection. Virology 276:229.[Medline]
  26. Badley, A. D., A. A. Pilon, A. Landay, D. H. Lynch. 2000. Mechanisms of HIV-associated lymphocyte apoptosis. Blood 96:2951.[Abstract/Free Full Text]
  27. Centers for Disease Control and Prevention. 1992. 1993 Revised classification system for HIV infection and expanded surveillance of definition for AIDS among adolescents and adults. Morbid. Mortal. Wkly. Rep. 41:1.
  28. Pakker, N. G., D. W. Notermans, R. J. de Boer, M. T. Roos, F. de Wolf, A. Hill, J. M. Leonard, S. A. Danner, F. Miedema, P. T. Schellekens. 1998. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat. Med. 4:208.[Medline]
  29. van der Vliet, H. J. J., N. Nishi, Y. Koezuka, M. A. Peyrat, B. M. E. von Blomberg, A. J. M. van den Eertwegh, H. M. Pinedo, G. Giaccone, R. J. Scheper. 1999. Effects of {alpha}-galactosylceramide (KRN7000), interleukin-12 and interleukin-7 on phenotype and cytokine profile of human V{alpha}24+V{beta}11+ T cells. Immunology 98:557.[Medline]
  30. Prussin, C., B. Foster. 1997. TCR V{alpha}24 and V{beta}11 coexpression defines a human NK1 T cell analog containing a unique Th0 subpopulation. J. Immunol. 159:5862.[Abstract]
  31. Flamand, L., R. W. Crowley, P. Lusso, S. Colombini-Hatch, D. M. Margolis, R. C. Gallo. 1998. Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis. Proc. Natl. Acad. Sci. USA 95:3111.[Abstract/Free Full Text]
  32. Yang, L. P., J. L. Riley, R. G. Carroll, C. H. June, J. Hoxie, B. K. Patterson, Y. Ohshima, R. J. Hodes, G. Delespesse. 1998. Productive infection of neonatal CD8+ T lymphocytes by HIV-1. J. Exp. Med. 187:1139.[Abstract/Free Full Text]
  33. Debatin, K. M., A. Fahrig-Faissner, S. Enenkel-Stoodt, W. Kreuz, A. Benner, P. H. Krammer. 1994. High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1 infected children. Blood 83:3101.[Free Full Text]
  34. Katsikis, P. D., E. S. Wunderlich, C. A. Smith, L. A. Herzenberg, L. A. Herzenberg. 1995. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J. Exp. Med. 181:2029.[Abstract/Free Full Text]
  35. Mitra, D., M. Steiner, D. H. Lynch, L. Staiano-Coico, J. Laurence. 1996. HIV-1 upregulates Fas ligand expression in CD4+ T cells in vitro and in vivo: association with Fas-mediated apoptosis and modulation by aurintricarboxylic acid. Immunology 87:581.[Medline]
  36. Silvestris, F., G. Camarda, P. Cafforio, F. Dammacco. 1998. Upregulation of Fas ligand secretion in non-lymphopenic stages of HIV-1 infection. AIDS 12:1103.[Medline]
  37. Hosaka, N., N. Oyaizu, M. H. Kaplan, H. Yagita, S. Pahwa. 1998. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons. Infect. Dis. 178:1030.
  38. Hazenberg, M. D., J. W. T. Cohen Stuart, S. A. Otto, J. C. C. Borleffs, C. A. B. Boucher, R. J. de Boer, F. Miedema, D. Hamann. 2000. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood. 95:249.[Abstract/Free Full Text]
  39. Matsuda, J. L., O. V. Naidenko, L. Gapin, T. Nakayama, M. Taniguchi, C.-R. Wang, Y. Koezuka, M. Kronenberg. 2000. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192:741.[Abstract/Free Full Text]
  40. Kopelman, R. G., S. Zola-Pazner. 1988. Association of human immunodeficiency virus infection and autoimmune phenomena. Am. J. Med. 84:82.[Medline]
  41. Morrow, W. J., D. A. Isenberg, R. E. Sobol, R. B. Stricker, T. Kieber-Emmons. 1991. AIDS virus infection and autoimmunity: a perspective of the clinical, immunological, and molecular origins of the autoallergic pathologies associated with HIV disease. Clin. Immunol. Immunopathol. 58:163.[Medline]
  42. Goedert, J. J.. 2000. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin. Oncol. 27:390.[Medline]
  43. Sumida, T., A. Sakamoto, H. Murata, Y. Makino, H. Takahashi, S. Yoshida, K. Nishioka, I. Iwamoto, M. Taniguchi. 1995. Selective reduction of T cells bearing invariant V{alpha}24J{alpha}Q antigen receptor in patients with systemic sclerosis. J. Exp. Med. 182:1163.[Abstract/Free Full Text]
  44. Wilson, S. B., S. C. Kent, K. T. Patton, T. Orban, R. A. Jackson, M. Exley, S. Porcelli, D. A. Schatz, M. A. Atkinson, S. P. Balk, et al 1998. Extreme Th1 bias of invariant V{alpha}24J{alpha}Q T cells in type 1 diabetes. Nature 391:177.[Medline]
  45. van der Vliet, H. J. J., B. M. E. von Blomberg, N. Nishi, M. Reijm, A. E. Voskuyl, A. A. van Bodegraven, C. H. Polman, T. Rustemeyer, P. Lips, A. J. M. van den Eertwegh, et al 2001. Circulating V{alpha}24+V{beta}11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 100:144.[Medline]
  46. Kawano, T., T. Nakayama, N. Kamada, Y. Kaneko, M. Harada, N. Ogura, Y. Akutsu, S. Motohashi, T. Iizasa, H. Endo, et al 1999. Antitumor cytotoxicity mediated by ligand-activated human V{alpha}24+ NKT cells. Cancer Res. 59:5102.[Abstract/Free Full Text]
  47. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D. D. Donaldson, D. P. Carbone, W. E. Paul, J. A. Berzofsky. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1:515.[Medline]
  48. Miyamoto, K., S. Miyake, T. Yamamura. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing Th2 bias of natural killer T cells. Nature 413:531.[Medline]
  49. Kumar, V., V. Bhardwaj, L. Soares, J. Alexander, A. Sette, E. Sercarz. 1995. Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon {gamma} by T cells. Proc. Natl. Acad. Sci. USA 92:9510.[Abstract/Free Full Text]
  50. Smyth, M. J., D. I. Godfrey. 2000. NKT cells and tumor immunity: a double-edged sword. Nat. Immunol. 1:459.[Medline]



This article has been cited by other articles:


Home page
J. Virol.Home page
C. S. Fernandez, A. C. Chan, K. Kyparissoudis, R. De Rose, D. I. Godfrey, and S. J. Kent
Peripheral NKT Cells in Simian Immunodeficiency Virus-Infected Macaques
J. Virol., February 15, 2009; 83(4): 1617 - 1624.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
O. M. Kattan, F. B. Kasravi, E. L. Elford, M. T. Schell, and H. W. Harris
Apolipoprotein E-Mediated Immune Regulation in Sepsis
J. Immunol., July 15, 2008; 181(2): 1399 - 1408.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
S. Vasan, M. A. Poles, A. Horowitz, E. E. Siladji, M. Markowitz, and M. Tsuji
Function of NKT cells, potential anti-HIV effector cells, are improved by beginning HAART during acute HIV-1 infection
Int. Immunol., August 16, 2007; (2007) dxm055v1.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. van der Vliet, H. Koon, and M. Exley
Effects of Interleukin-2 Treatment on CD1d-Restricted Natural Killer T Cells
Clin. Cancer Res., July 15, 2007; 13(14): 4311 - 4311.
[Full Text] [PDF]


Home page
J. Immunol.Home page
H. J. J. van der Vliet, M. G. A. van Vonderen, J. W. Molling, H. J. Bontkes, M. Reijm, P. Reiss, M. A. van Agtmael, S. A. Danner, A. J. M. van den Eertwegh, B. M. E. von Blomberg, et al.
Cutting Edge: Rapid Recovery of NKT Cells upon Institution of Highly Active Antiretroviral Therapy for HIV-1 Infection
J. Immunol., November 1, 2006; 177(9): 5775 - 5778.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. J. Raftery, F. Winau, S. H. E. Kaufmann, U. E. Schaible, and G. Schonrich
CD1 Antigen Presentation by Human Dendritic Cells as a Target for Herpes Simplex Virus Immune Evasion
J. Immunol., November 1, 2006; 177(9): 6207 - 6214.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
P. O. Ilyinskii, R. Wang, S. P. Balk, and M. A. Exley
CD1d Mediates T-Cell-Dependent Resistance to Secondary Infection with Encephalomyocarditis Virus (EMCV) In Vitro and Immune Response to EMCV Infection In Vivo
J. Virol., July 15, 2006; 80(14): 7146 - 7158.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
H. Lin, M. Nieda, J. F. Hutton, V. Rozenkov, and A. J. Nicol
Comparative gene expression analysis of NKT cell subpopulations
J. Leukoc. Biol., July 1, 2006; 80(1): 164 - 173.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Unutmaz
Reviving the killers: all you need is IL-2
Blood, April 15, 2006; 107(8): 3021 - 3022.
[Full Text] [PDF]


Home page
BloodHome page
M. Moll, J. Snyder-Cappione, G. Spotts, F. M. Hecht, J. K. Sandberg, and D. F. Nixon
Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2
Blood, April 15, 2006; 107(8): 3081 - 3083.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
D. E. Wesche, J. L. Lomas-Neira, M. Perl, C.-S. Chung, and A. Ayala
Leukocyte apoptosis and its significance in sepsis and shock
J. Leukoc. Biol., August 1, 2005; 78(2): 325 - 337.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Ronet, S. Darche, M. L. de Moraes, S. Miyake, T. Yamamura, J. A. Louis, L. H. Kasper, and D. Buzoni-Gatel
NKT Cells Are Critical for the Initiation of an Inflammatory Bowel Response against Toxoplasma gondii
J. Immunol., July 15, 2005; 175(2): 899 - 908.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Ishikawa, S. Motohashi, E. Ishikawa, H. Fuchida, K. Higashino, M. Otsuji, T. Iizasa, T. Nakayama, M. Taniguchi, and T. Fujisawa
A Phase I Study of {alpha}-Galactosylceramide (KRN7000)-Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer
Clin. Cancer Res., March 1, 2005; 11(5): 1910 - 1917.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Ahmad and F. Alvarez
Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis
J. Leukoc. Biol., October 1, 2004; 76(4): 743 - 759.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. K. Sandberg, C. A. Stoddart, F. Brilot, K. A. Jordan, and D. F. Nixon
Development of innate CD4+ {alpha}-chain variable gene segment 24 (V{alpha}24) natural killer T cells in the early human fetal thymus is regulated by IL-7
PNAS, May 4, 2004; 101(18): 7058 - 7063.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
A. Motsinger, A. Azimzadeh, A. K. Stanic, R. P. Johnson, L. Van Kaer, S. Joyce, and D. Unutmaz
Identification and Simian Immunodeficiency Virus Infection of CD1d-Restricted Macaque Natural Killer T Cells
J. Virol., July 15, 2003; 77(14): 8153 - 8158.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. Lucas, S. Gadola, U. Meier, N. T. Young, G. Harcourt, A. Karadimitris, N. Coumi, D. Brown, G. Dusheiko, V. Cerundolo, et al.
Frequency and Phenotype of Circulating V{alpha}24/V{beta}11 Double-Positive Natural Killer T Cells during Hepatitis C Virus Infection
J. Virol., February 1, 2003; 77(3): 2251 - 2257.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. B. Gurney, O. O. Yang, S. B. Wilson, and C. H. Uittenbogaart
TCR{gamma}{delta}+ and CD161+ Thymocytes Express HIV-1 in the SCID-hu Mouse, Potentially Contributing to Immune Dysfunction in HIV Infection
J. Immunol., November 1, 2002; 169(9): 5338 - 5346.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Y. Oikawa, A. Shimada, S. Yamada, Y. Motohashi, Y. Nakagawa, J.-i. Irie, T. Maruyama, and T. Saruta
High Frequency of V{alpha}24+ V{beta}11+ T-Cells Observed in Type 1 Diabetes
Diabetes Care, October 1, 2002; 25(10): 1818 - 1823.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van der Vliet, H. J. J.
Right arrow Articles by Pinedo, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Vliet, H. J. J.
Right arrow Articles by Pinedo, H. M.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS